solidcolours / iStockphoto.com
22 October 2018Americas
AbbVie enters Humira licensing deal with Fresenius Kabi
AbbVie has announced that it has entered into a licensing deal with Germany-based pharmaceutical company Fresenius Kabi.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
29 September 2017 AbbVie has settled its patent dispute over Amgen’s proposed biosimilar for Humira (adalimumab), a drug used to treat multiple types of arthritis as well as psoriasis.
Americas
18 July 2018 US-based biopharmaceutical company AbbVie entered into a patent licensing agreement with generics company Mylan yesterday.
Editor's picks
Editor's picks
Americas
29 September 2017 AbbVie has settled its patent dispute over Amgen’s proposed biosimilar for Humira (adalimumab), a drug used to treat multiple types of arthritis as well as psoriasis.
Americas
18 July 2018 US-based biopharmaceutical company AbbVie entered into a patent licensing agreement with generics company Mylan yesterday.
Americas
29 September 2017 AbbVie has settled its patent dispute over Amgen’s proposed biosimilar for Humira (adalimumab), a drug used to treat multiple types of arthritis as well as psoriasis.
Americas
18 July 2018 US-based biopharmaceutical company AbbVie entered into a patent licensing agreement with generics company Mylan yesterday.